Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISH 2022 | Inotuzumab ozogamicin and blinatumomab prior to and after alloHSCT in R/R Ph+ ALL

Naoki Hosen • 8 Oct 2022
ISH 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Inotuzumab ozogamicin

Naoki Hosen, PhD, Osaka University Graduate School of Medicine, Osaka, Japan, comments on the use of inotuzumab ozogamicin and blinatumomab prior to and after allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with relapsed/refractory (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). This interview took place at the 38th World Congress of the International Society of Hematology 2022.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Naoki Hosen

Novel targets in CAR-T therapy for multiple myeloma: integrin beta-7 & CD98 heavy chain
0:47
Novel targets in CAR-T therapy for multiple myeloma: integrin beta-7 & CD98 heavy chain
Naoki Hosen • 8 Oct 2022

Related Videos

Precision intervention strategies in clonal hematopoiesis and CCUS
11:48
Precision intervention strategies in clonal hematopoiesis and CCUS
Kelly Bolton • 3 Oct 2026
Response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusions
11:38
Response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusions
William Shomali • 3 Oct 2026
Revising response criteria for CMML and MDS/MPN overlap syndromes
12:28
Revising response criteria for CMML and MDS/MPN overlap syndromes
Somedeb Ball • 3 Oct 2026
JAK inhibitors and emerging therapies for MDS/MPN overlap syndromes
9:51
JAK inhibitors and emerging therapies for MDS/MPN overlap syndromes
Abdulraheem Yacoub • 3 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals